ERBB2 and breast cancer: As shown in Figure S1A, LncCCAT1 overexpression predicts a poor prognosis in patients with Luminal A breast cancer (n=256, P<0.05) while has no significant relationship with prognosis in patients with Luminal B (n=63), Triple-negative/basal-like (n=64) or HER2-enriched (n=22) breast cancer (data not shown), which might be due to the small sample sizes of Luminal B, Triple-negative/basal-like and HER2-enriched breast cancer patients.